| 書目名稱 | Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia | | 編輯 | Masahiro Kizaki | | 視頻video | http://file.papertrans.cn/639/638447/638447.mp4 | | 概述 | Is a comprehensive, high-level clinical reference on the pathogenesis and therapy of hematological malignancies.Provides the clinical experience of TKIs such as imatinib, nilotinib, dasatinib, and pon | | 圖書封面 |  | | 描述 | .Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia provides a comprehensive understanding of the recent molecular genetics of Chronic Myelogenous Leukemia (CML) and a characterization of the molecular targets for drug development. Included are therapeutic implications, diagnosis, and prognosis for understanding and facilitating daily practice in the management of patients with CML..Understanding of the pathogenesis and therapy of hematological malignancies such as CML has grown significantly in recent years. This development owe much to the progress in molecular biology and now makes a major contribution to diagnosis and to treatment that pharmacologically targets the molecular events of CML. Molecular targeting therapy with newly developed agents such as small molecules and antibodies for hematological malignancies are being discovered after years of research. Some of these, including tyrosine kinase inhibitors such as imatinib, nilotinib, and dasatinib, lead to increased survival rates and improved therapies. With the opinion leaders of basic and clinical research in the field as authors, this book reviews recent advances in the biology of CML.. | | 出版日期 | Book 2016 | | 關(guān)鍵詞 | Chronic Myeloid Leukemia; Molecular-targeting thrapy; Stem Cell; TKI; Tyrosine Kinase Inhibitor; molecula | | 版次 | 1 | | doi | https://doi.org/10.1007/978-4-431-55714-2 | | isbn_softcover | 978-4-431-56255-9 | | isbn_ebook | 978-4-431-55714-2 | | copyright | Springer Japan 2016 |
The information of publication is updating
|
|
|Archiver|手機(jī)版|小黑屋|
派博傳思國際
( 京公網(wǎng)安備110108008328)
GMT+8, 2025-10-29 18:56
發(fā)表于 2025-3-21 16:59:21
